Valdecoxib does not interfere with the CYP2D6 substrate metoprolol

Area of Science:

• Pharmacology
• Drug Metabolism
• Clinical Pharmacology

Background:

• Cytochrome P450 (CYP)2D6 plays a crucial role in drug metabolism.
• Previous research indicated celecoxib inhibits CYP2D6 activity.
• Valdecoxib, a metabolite of parecoxib, was also suspected to interact with CYP2D6 substrates, necessitating further investigation.

Purpose of the Study:

• To evaluate the impact of valdecoxib on the pharmacokinetics of metoprolol, a CYP2D6 substrate.
• To assess potential drug-drug interactions between COX-2 inhibitors and CYP2D6 substrates.

Main Methods:

• A randomized, 3-period crossover study involving 15 healthy male volunteers.
• Volunteers received metoprolol (50 mg) alone or after 7-day pre-treatment with valdecoxib (20 mg/day) or rofecoxib (25 mg/day).
• Pharmacokinetic and pharmacodynamic parameters of metoprolol were analyzed.

Main Results:

• Valdecoxib and rofecoxib did not significantly alter the area under the plasma concentration-time curve of metoprolol.
• No significant changes in pharmacokinetic or pharmacodynamic parameters of metoprolol were observed.
• Higher doses of metoprolol also showed no interaction.

Conclusions:

• Therapeutic doses of valdecoxib and rofecoxib do not inhibit the CYP2D6-mediated metabolism of metoprolol.
• These findings suggest a lack of significant drug-drug interaction between these COX-2 inhibitors and metoprolol.
• Clinical implications for perioperative use of parecoxib regarding CYP2D6 substrate interactions are minimal at therapeutic doses.